Travere Therapeutics (TVTX) EBIT (2011 - 2026)
Travere Therapeutics (TVTX) reported EBIT of -$36.9 million for Q1 2026, up 13.5% on a YoY basis from -$32.5 million in Q1 2025, and down 13.84% quarter-over-quarter from -$32.4 million in Q4 2025.
Travere Therapeutics (TVTX) EBIT (2011 - 2026) Analysis & Trends
Travere Therapeutics has reported EBIT for 16 years, with the latest figure at -$36.9 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT rose 13.5% year-over-year to -$36.9 million; the trailing twelve-month figure through Mar 2026 stood at -$57.1 million (up 74.89% YoY), and the FY2025 full-year result was -$62.8 million, up 80.6% from the prior year.
- EBIT for Q1 2026 stood at -$36.9 million, down from -$32.4 million in the prior quarter.
- The five-year high for EBIT was $24.9 million in Q3 2025, with the low at -$139.2 million in Q1 2024.
- Historically, EBIT has averaged -$66.6 million across 5 years, with a median of -$72.0 million in 2022.
- Annual changes were most pronounced in 2022 — EBIT tumbled 160.49% — and 2025, when it surged 144.4%.
- Travere Therapeutics' EBIT stood at -$86.7 million in 2022, then slipped by 8.69% to -$94.2 million in 2023, then soared by 35.55% to -$60.7 million in 2024, then soared by 46.61% to -$32.4 million in 2025, then dropped by 13.84% to -$36.9 million in 2026.
- The last three EBIT figures came in at -$36.9 million (Q1 2026), -$32.4 million (Q4 2025), and $24.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Travere Therapeutics | 5.07 Bn | 4.99 Bn | 102.38 Mn | -36.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.92 Mn |
| Dec 31, 2025 | -32.43 Mn |
| Sep 30, 2025 | 24.93 Mn |
| Jun 30, 2025 | -12.65 Mn |
| Mar 31, 2025 | -42.67 Mn |
| Dec 31, 2024 | -60.74 Mn |
| Sep 30, 2024 | -56.15 Mn |
| Jun 30, 2024 | -67.70 Mn |
| Mar 31, 2024 | -139.24 Mn |
| Dec 31, 2023 | -94.23 Mn |
| Sep 30, 2023 | -92.59 Mn |
| Jun 30, 2023 | -103.95 Mn |
| Mar 31, 2023 | -97.37 Mn |
| Dec 31, 2022 | -86.70 Mn |
| Sep 30, 2022 | -82.60 Mn |
| Jun 30, 2022 | -78.53 Mn |
| Mar 31, 2022 | -71.98 Mn |
| Dec 31, 2021 | -84.85 Mn |
| Sep 30, 2021 | -31.71 Mn |
| Jun 30, 2021 | -35.32 Mn |